

## **Inotersen and Patisiran for Hereditary Transthyretin Amyloidosis: Effectiveness and Value**

### **Key Stakeholder Organizations**

ICER has identified the following organizations as key stakeholders for its upcoming report on treatments for Hereditary Transthyretin Amyloidosis. ICER will invite input from the following organizations, and welcomes suggestions from the broader community on additional organizations to add to this list. ICER often receives comments from individual patients and clinicians, and invites the public to submit recommendations for key stakeholders in these categories.

For a complete list of key dates and opportunities for input on this project, please visit [ICER's website](#).

- Akcea Therapeutics
- Alnylam Pharmaceuticals
- Amyloidosis Foundation
- Amyloidosis Research Consortium
- Amyloidosis Support Groups